Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Jun 22, 2018
Open Peer Review Period: Jun 25, 2018 - Aug 1, 2018
Date Accepted: Sep 10, 2018
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Web-Based Patient-Reported Outcomes Using the International Consortium for Health Outcome Measurement Dataset in a Major German University Hospital: Observational Study

Karsten MM, Speiser D, Hartmann C, Zeuschner N, Lippold K, Kiver V, Gocke P, Kirchberger V, Blohmer JU

Web-Based Patient-Reported Outcomes Using the International Consortium for Health Outcome Measurement Dataset in a Major German University Hospital: Observational Study

JMIR Cancer 2018;4(2):e11373

DOI: 10.2196/11373

PMID: 30573450

PMCID: 6320408

Web-Based Patient-Reported Outcomes Using the International Consortium for Health Outcome Measurement Dataset in a Major German University Hospital: An Observational Study

  • Maria M Karsten; 
  • Dorothee Speiser; 
  • Claudia Hartmann; 
  • Nele Zeuschner; 
  • Kai Lippold; 
  • Verena Kiver; 
  • Peter Gocke; 
  • Valerie Kirchberger; 
  • Jens-Uwe Blohmer

ABSTRACT

Background:

Collecting patient-reported outcome (PRO) data systematically enables objective evaluation of treatment and its related outcomes. Using disease-specific questionnaires developed by the International Consortium for Health Outcome Measurement (ICHOM) allows for comparison between physicians, hospitals, and even different countries.

Objective:

This pilot project aimed to establish a digital system to measure PROs for new patients with breast cancer who attended the Charité Breast Center This approach should serve as a blueprint to further expand the PRO measurement to other disease entities and departments.

Methods:

In November 2016, we implemented a Web-based system to collect PRO data at Charité Breast Center using the ICHOM dataset. All new patients at the Breast Center were enrolled and answered a predefined set of questions using a tablet computer. Once they started their treatment at Charité, automated emails were sent to the patients at predefined treatment points. Those emails contained a Web-based link through which they could access and answer questionnaires.

Results:

By now, 541 patients have been enrolled and 2470 questionnaires initiated. Overall, 9.4% (51/541) of the patients were under the age of 40 years, 49.7% (269/541) between 40 and 60 years, 39.6% (214/541) between 60 and 80 years, and 1.3% (7/541) over the age of 80 years. The average return rate of questionnaires was 67.0%. When asked about the preference regarding paper versus Web-based questionnaires, 6.0% (8/134) of the patients between 50 and 60 years, 6.0% (9/150) between 60 and 70 years, and 12.7% (9/71) over the age of 70 years preferred paper versions.

Conclusions:

Measuring PRO in patients with breast cancer in an automated electronic version is possible across all age ranges while simultaneously achieving a high return rate.


 Citation

Please cite as:

Karsten MM, Speiser D, Hartmann C, Zeuschner N, Lippold K, Kiver V, Gocke P, Kirchberger V, Blohmer JU

Web-Based Patient-Reported Outcomes Using the International Consortium for Health Outcome Measurement Dataset in a Major German University Hospital: Observational Study

JMIR Cancer 2018;4(2):e11373

DOI: 10.2196/11373

PMID: 30573450

PMCID: 6320408

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.